FASLG and colitis: We systemically infused GMSCs, ASA-iGMSCs, and ASA-treated FasL-knockdown iGMSCs into colitis mice and found that ASA was not able to rescue the therapeutic effects of iGMSCs with si-FasL treatment, the phenotype of which displayed decreased body weight, exacerbated colonic inflammation, increased DAI, and recovered colitis HAI, compared to the iGMSC-treated group (Fig. 4d–f).